Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1653372 | 0.98 | SLC18A3 (0.49) | SLC18A3SIGMAR1HPGDSMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL311386 | 0.98 | SLC18A3 (0.49) | SLC18A3SIGMAR1HPGDSMEN1KMT2A | |
| SCHEMBL6166041 | 0.97 | SLC18A3 (0.47) | SLC18A3SIGMAR1HPGDSMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6806273 | 0.95 | SLC18A3 (0.46) | SLC18A3SIGMAR1HPGDSMEN1KMT2A | |
| SCHEMBL2315850 | 0.87 | HPGDS (0.61) | SLC18A3SIGMAR1HPGDSMEN1KMT2A | |
| SCHEMBL242610 | 0.85 | ADORA1 (0.52) | ADORA3ADORA2BADORA1ADORA2A | |
| SCHEMBL27776218 | 0.84 | HTR3A (0.46) | SLC18A3SIGMAR1KMT2AGABRA1HTR2C | |
| SCHEMBL311619 | 0.84 | MKNK1 (0.54) | HTR2CHTR2A | |
| SCHEMBL4670822 | 0.84 | ADORA3 (0.40) | HPGDSMEN1KMT2AKCNH2ADORA3 | |
| SCHEMBL27776222 | 0.84 | GABRA1 (0.46) | GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105646492-A | Five-membered-aromatic-heterocycte-containing substituted xanthine compound and preparation method and use thereof | 中国医学科学院药物研究所 | 2016-06-08 | — | — | CN | disclosed |
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8609696-B2 | Serotonin 5-HT2B receptor inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| CN-101679439-B | P70S 6 kinase inhibitors | LILLY CO ELI | 2013-09-11 | — | — | CN | disclosed |
| EP-2308869-B1 | AZOLE COMPOUND | ASTELLAS PHARMA INC (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2379524-A1 | SEROTONIN 5-HT2B RECEPTOR INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-10-26 | — | — | EP | disclosed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| CN-1093125-C | Sulfamide-metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2002-10-23 | — | — | CN | disclosed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6376506-B1 | REACTING SULFAMOYL OXAZOLIDONE WITH (1,2,3,4)-TETRAHYDRO-BETA-CARBOLINE TO FORM INHIBITOR; USED TO TREAT ARTHRITIS, OSTEOPOROSIS, PERIODONTAL DISEASE, CARDIOVASCULAR DISEASES, MULTIPLE SCLEROSIS, AND TUMORS | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6143744-A | Sulfamide-metalloprotease inhibitors | SYNTEX (U.S.A.) INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6130220-A | ENZYME INHIBITORS | SYNTEX (USA) INC. (US) | 2000-10-10 | — | — | US | disclosed |
| CN-1250445-A | Sulfamide-metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2000-04-12 | — | — | CN | disclosed |
| US-5998412-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | SYNTEX (U.S.A.) INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0958287-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | HTR2B, HTR1B, HTR3B | SLC18A3 52/4885SIGMAR1 141/4885HPGDS 586/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | SLC18A3 4126/4885SIGMAR1 1797/4885HPGDS 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.